NEWRON PHARMACEUT. EO-20
Newron Pharmaceuticals S.p.A., a biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson's in the European Union, the United Kingdom, the United States, Latin America, Switzerland, and Japan. The company's… Read more
NEWRON PHARMACEUT. EO-20 - Asset Resilience Ratio
NEWRON PHARMACEUT. EO-20 (NP5) has an Asset Resilience Ratio of 26.97% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2009–2024)
This chart shows how NEWRON PHARMACEUT. EO-20's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down NEWRON PHARMACEUT. EO-20's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €16.56 Million | 26.97% |
| Total Liquid Assets | €16.56 Million | 26.97% |
Asset Resilience Insights
- Very High Liquidity: NEWRON PHARMACEUT. EO-20 maintains exceptional liquid asset reserves at 26.97% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
NEWRON PHARMACEUT. EO-20 Industry Peers by Asset Resilience Ratio
Compare NEWRON PHARMACEUT. EO-20's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for NEWRON PHARMACEUT. EO-20 (2009–2024)
The table below shows the annual Asset Resilience Ratio data for NEWRON PHARMACEUT. EO-20.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 4.53% | €2.89 Million | €63.91 Million | -19.68pp |
| 2023-12-31 | 24.21% | €6.26 Million | €25.87 Million | -0.93pp |
| 2022-12-31 | 25.14% | €9.35 Million | €37.20 Million | +6.17pp |
| 2021-12-31 | 18.97% | €9.57 Million | €50.49 Million | -16.26pp |
| 2020-12-31 | 35.23% | €18.04 Million | €51.20 Million | +6.85pp |
| 2019-12-31 | 28.38% | €17.11 Million | €60.29 Million | +1.33pp |
| 2018-12-31 | 27.05% | €16.23 Million | €60.00 Million | +0.43pp |
| 2017-12-31 | 26.62% | €19.44 Million | €73.02 Million | +20.40pp |
| 2016-12-31 | 6.22% | €3.52 Million | €56.59 Million | -4.87pp |
| 2015-12-31 | 11.09% | €4.92 Million | €44.38 Million | -7.65pp |
| 2014-12-31 | 18.74% | €6.95 Million | €37.07 Million | +1.48pp |
| 2013-12-31 | 17.26% | €5.46 Million | €31.62 Million | +9.10pp |
| 2012-12-31 | 8.16% | €3.64 Million | €44.65 Million | +4.30pp |
| 2009-12-31 | 3.85% | €1.60 Million | €41.68 Million | -- |